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Alkytating agents comprise a miscellaneous group 
of substances, which are able to release alkylating 
entities either at the site of application, or in the 
course of their metabolism in the liver and in other 
organs. Alkylating agents came into prominence when 
some members of this groups were found to possess 
anti-tumour action, often associated with carcino- 
genic and mutagenic activity [1,2]. Their interaction 
with cellular macromolecules, the nucleic acids in 
particular, have been extensively studied, but little 
attention has been paid to alkylations of coenzymes. 
The coenzymes in which vitamins of the B group are 
essential constituents, though few in number are 
responsible for the functioning of a great many 
enzymes, and accordingly are of paramount impor- 
tance for cellular biochemical processes. In this paper 
the possibility is discussed that alkylation of coen- 
zymes may be the biochemical basis of the acute and 
subacute ffects of alkylating hepatotoxins. 
Hepatotoxic and hepatocarcinogenic compounds 
(such as pyrrolizidine alkaloids, dialkylnitrosamines, 
etc.) are likely to undergo activation in the liver by 
more than one pathway, and to produce various 
metabolic intermediates, including bifunctional 
entities, as well as some alkylating species, in the 
form of free radicals, carbonium ions, etc. 
The carcinogenic effects of such substances are 
probably initiated by the bifunctional metabolites, 
which being able to crosslink macromolecules in the 
chromatin could have long lasting consequences [3]. 
However, the more acute lesions: liver necrosis, fatty 
inf'iltration etc. appear to be consistent with inacti- 
vation of certain coenzymes and of their component 
B vitamins by alkylating entities, substituting the 
reactive C, N or O position in their molecules. 
The lesions produced by a single dose of a hepato- 
toxin depend on its size, route of administration, the 
time interval after dosing and also on the species, 
age, sex and the nutritional status of the animal. The 
livers of animals which die within 2-3 days after an 
appropriate dose of such hepatotoxins usually present 
microscopically a composite pattern of changes 
within the liver lobules: the cells surrounding the 
portal triads may retain normal appearance, those in 
the midzonal areas show varying degrees of fatty 
infiltration and glycogen loss, while round the central 
veins there are more or less extensive areas of necrosis. 
Necrotic lesions appear to correlate with depletion of 
NAD coenzymes, while the fatty lesions may be the 
result of deprivation mainly of CoA and folates. 
Enzymes deprived of their coenzymes are less stable 
and are more readily inactivated than holoenzymes 
[4]. 
Attention has already been drawn to the fact that 
nicotinamide alkylated at its ring nitrogen to N-1- 
alkylnicotinamide, could not be used for the biosyn- 
thesis of NAD coenzymes essential for the electron 
transport chain and a multitude of enzymic reactions 
[5]. Decrease of NAD coenzymes i  known to occur 
in the liver of animals given carbon tetrachloride [6], 
azaserine [7], heliotrine [8], dimethylnitrosamine 
[9,10], streptozotocin etc. [9,10] and to be due to a 
decrease of the biosynthesis of these coenzymes. 
Increased urinary excretion of N-l-methylnicotin- 
amide has been reported after azaserine [7], dimethyl- 
nitrosamine and several other alkylating agents [12]. 
Large doses of nicotinamide given at the time of 
dosing with the alkylating hepatotoxins will prevent 
the lowering of NAD coenzymes [6,8,13,14] and 
sometimes protect against liver necrosis [6,15] ; the 
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Fig. 1. Nicotinamide-adenine dinucleotide coenzyme. 
nicotinamide possibly acting as scavenger of the alkyl 
entities. Nicotinamide treatment did not prevent the 
development of tumours by streptozotocin [ 141 or 
heliotrine [ 151 . 
Among the components of NAD coenzymes (fig. 1.) 
the adenine and ribose can be biosynthesised in the 
body, phosphoric acid moieties are abundant, but 
the nicotinamide [one of the vitamin B group) has to 
be supplied from mainly dietary sources, and would 
be a limiting factor when suddenly it is lost due to 
alkylation. 
The blood entering the portal veins brings to the 
liver lobules the nutrients absorbed from the gastro- 
intestinal tract, that contain the B vitamins derived 
from the diet and from the metabolic activities of the 
intestinal microorganisms. The B vitamins would be 
used by the hepatocytes for the biosynthesis of the 
various cofactors, hence their concentration will 
decrease gradually as the blood passes towards the 
central veins. Liver cells in the centrilobular zones 
being less well supplied with the B vitamins will be 
more liable to coenzyme depletion, and more vulner- 
able to alkylations. This may partly explain the 
frequent occurrence of necrotic lesions in the centri- 
lobular zones by the action of compounds activated 
in the liver. However, the localization in the liver 
lobules of the enzymes which activate specific com- 
pounds is obviously the determining factor. 
Large doses of hepatotoxins cause liver necrosis, 
but when the doses are appropriately reduced to be 
compatible with cell survival, fatty infiltration and 
glycogen loss may occur. Alkylating entities could 
react with various cell constituents, and would pro- 
bably do so according to the respective affinities of 
the receptor groups. Of the latter, end-thiols are 
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Fig.2. Coenzyme A. 
known to have the highest affinities and would be 
preferentially substituted by alkylating entities (for 
references ee [2] ). Among compounds containing 
end-thiols, CoA, (fig.2) though its concentration in 
the liver (about 200 mg/kg fresh tissue) is only 
about 1 : 10 of that of glutathione, is likely to be 
preferentially alkylated. The thiol group in CoA is 
very reactive, as evidenced by its formation of thi- 
oesters with various metabolic acids. The function 
of CoA in the metabolism of fats and of carbohy- 
drates, in the acetylation of choline and of aromatic 
amines, etc., depends on the reversible formation of 
thioesters [ 161. However, on alkylation CoA will 
form thioethers; these being relatively stable will 
prevent the formation of thioesters, and thus inhibit 
the functioning of CoA. 
In a careful study of the changes in the liver con- 
tent of trichloroacetic acid soluble thiols in animals 
given azo dyes, Dijkstra [ 171 has shown that an 
immediate fall is followed by a rise beginning about 
4 h and reaches a maximum at about 48 h after a 
single dose. The soluble thiols have been usually 
interpreted as representing the reduced glutathione 
of the liver. The possibility that the thiol-group of 
CoA might be included in the estimations of soluble 
thiols has not been considered. It is not unlikely that 
disregard of CoA might have been responsible for 
the conflicting results encountered in the course of 
investigations into the effects of toxic and carcin- 
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ogenic compounds on the acid soluble thiols [ 181. 
It is of interest that Leaf and Neuberger [ 191 
already in 1947 facing discrepancies in the results 
obtained using various methods of estimation of 
liver glutathione in the course of dietary deficiencies, 
suggested that ‘a diet which may produce liver lesions, 
reduces considerably the glutathione content of the 
liver and probably also the concentration of other 
low molecular sulphur-containing compounds’. (The 
italics are mine). 
Sulphydryl compounds, especially cysteamine, 
will protect animals from acute effects of alkylating 
hepatotoxins and prevent the fatty infiltration and 
glycogen loss of hepatocytes [20]. However, as in the 
case of nicotinamide, sulphydryl compounds do not 
protect from the induction of tumours [21]. 
Folates, which in conjunction with coenzyme Brz 
are involved in lipid metabolism, are likely to be also 
affected by alkylations. These cofactors function as 
carriers of one carbon units, and are involved in the 
biosynthesis, inter alia, of the lipotropes, choline and 
methionine. In order to exert this function, folic 
acid (fig.3) is reduced and via the S,lO-methylene 
intermediate forms 5methyltetrahydrofolic acid, 
polyglutamates, etc. [22,22a]. It seems justified to 
expect that the alkylating entities released from 
hepatotoxins, even when they consist of more than 
one carbon unit, might alkylate folic acid. The 
resulting derivatives of folic acid, having bulky 
constituents might not be functional, but if able to 
function, would lead to the biosynthesis of unphysio- 
logical compounds, such as ethionine, or its higher 
homologues and analogues, analogues of choline, of 
purines etc. Whether such compounds are actually 
formed can at present only be surmised; appropriate 
studies have yet to be made. 
Though the detailed mechanism of action of 
coenzyme Brz in intracellular methylations still 
remains to be elucidated, the role of the cobalt atom 
bound inside the macrocyclic tetrapyrrol structure 
YOOH 
Fig.3. Folic acid. 
Fig.4, Porphyrin tetrapyrrol macrocycle. 
[23] is known to be of paramount importance. 
Similarly, the iron in haem in essential for electron 
or oxygen transport by cytochromes, haemoglobins, 
catalase, etc. In the absence of the metal atom, bound 
and coordinated with the nitrogens of the tetrapyrrole 
(f&.4.) macrocycles, porphyrins (and corrins) could 
not function. Methylation in vitro of porphyrins 
leads to mono-, di- and tri-methyl derivatives, in which 
the methyl groups substitute the pyrrole nitrogens. 
The methylated porphyrins appear to be able to bind 
metal atoms, but the biological functioning of such 
methylated ‘pseudo-haems’ is not yet known (for 
references see [23] ). It is not unlikely, that in vivo 
the pyrrole nitrogens could also become alkylated by 
alkylating hepatotoxins. However, when bulky alkyla- 
ting moieties substitute nitrogens in the tetrapyrrole 
macrocycles, these might prevent the insertion of the 
metal. Such substituted macrocyclic tetrapyrroles 
would obviously not be functional; they may be 
excreted and simulate porphyrias (as in the case of 
ethionine [24] ), or form the respective linear tetra- 
pyrrole oxidation products, analogous to bile pig- 
ments, and cause jaundice etc. The key role of NAD 
coenzymes and the interdependence of biochemical 
reactions is illustrated by the reported prevention of 
the allylisopropylacetamide induced porphyria by 
pretreatment with nicotinic acid [25]. 
In this short paper I restricted myself to a discussion 
of the possible effects on the liver of alkylations in 
vivo of cofactors (such as NAD coenzymes, CoA, 
folates, coenzyme Br2 and the haems) at their most 
reactive positions. However, this does not mean that 
other cofactors may not be alkylated, nor that alkylat- 
ing entities in statu nascendi might not substitute 
also other positions in the coenzymes. Additional 
targets for alkylations could be positions which are 
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involved in the binding of the respective substrates 
and apoenzymes; their substitution would obviously 
also impair the functioning of the coenzymes. 
Whether and how specific alkylating compounds 
affect the integrity of coenzymes and of the respective 
B vitamin-components in relation to liver injury 
remains to be experimentally investigated. Such data 
are not yet available (compare e.g. [26,27] ). 
The new concept presented in this paper, that the 
biochemical basis of liver injury by alkylating hepato- 
toxins may, to some extent, be due to alkylation of 
coenzymes and to the in vivo formation of anti- 
vitamins, if proved correct, implies that in certain 
cases appropriate treatment with B vitamins might 
prevent the more acute liver lesions. However, the 
induction of tumours by these agents would not be 
prevented. 
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